Secrutinzers Report and Voting Results for AGM held on 19.09.2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Oxygenta Pharmaceutical held its 32nd AGM on 19 September 2025 via video conferencing, attended by 61 members, and all 14 resolutions were passed with near-unanimous approval (99.98%–99.99%). Key items included adoption of FY25 audited financial statements, re-appointment/appointment of six directors (including whole-time, non-executive, and three independent directors), and ratification of cost auditor remuneration. Shareholders also approved raising the company's borrowing limit under Section 180(1)(c) to up to Rs. 200 crore, and creating mortgages/charges on company assets to support that borrowing. Material related party transactions with holding company Virupaksha Organics Limited — covering sale/purchase and loan/guarantee arrangements — were also approved. Members praised the management's execution of the acquisition/takeover by Virupaksha Organics and asked about the post-acquisition financial outlook.
The expanded Rs. 200 crore borrowing limit and large related-party transactions with the holding company signal significant corporate activity and potential debt/funding expansion post-acquisition. Near-unanimous shareholder approval across all resolutions indicates no governance pushback, though retail investors should watch the scale of related-party dealings with Virupaksha Organics going forward.